Literature DB >> 29797475

Clinical value of jointly detection pleural fluid Midkine, pleural fluid adenosine deaminase, and pleural fluid carbohydrate antigen 125 in the identification of nonsmall cell lung cancer-associated malignant pleural effusion.

Fan Zhang1, Junjun Wang1, Xiaoyong Zheng1, Lijuan Hu1, Jie Chen2, Feng Jiang1, Yumin Wang1.   

Abstract

BACKGROUND: Midkine (MK) level has been shown to be elevated in serum of patients with nonsmall cell lung cancer (NSCLC). However, the diagnostic value of MK in pleural effusion in NSCLC has not been well validated and established.
METHODS: Samples of NSCLC-associated malignant pleural effusions (MPE) and benign effusions (BPE) were collected. The pleural fluid MK (pMK), pleural fluid adenosine deaminase (pADA), pleural fluid lactate dehydrogenase (pLDH), pleural fluid glucose (pGLU), pleural fluid ferritin (pFER), pleural fluid CA199 (pCA199), pleural fluid CA125 (pCA125), pleural effusion white cell count (pWBC), and pleural effusion red cell count (pRBC) were analyzed, and the clinical data of each group were collected for statistical analysis. RESULT: The level of pMK, pCA125, pMK + pCA125, and pMK + pCA125 + pADA in the MPE was significantly higher than the BPE group (P = .003, .000, .000, .000). The pADA level in the BPE was significantly higher than the MPE group (P = .003). It showed that the area under the ROC curve (AUC) (0.816) of jointly detection pMK, pCA125, and pADA was significantly higher than other markers for the diagnosis of MPE. Therefore, joint detection of pMK + pCA125 + pADA suggested that the sensitivity, specificity, and AUC was 82.54%, 74.19% at the cutoff 0.47 and diagnostic performance was higher than others.
CONCLUSION: Joint detection of pMK + pCA125 + pADA can be used as a good indicator for the identification of MPE of NSCLC.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Midkine; adenosine deaminase; malignant pleural effusion; nonsmall cell lung cancer; pleural fluid carbohydrate antigen 125

Mesh:

Substances:

Year:  2018        PMID: 29797475      PMCID: PMC6817252          DOI: 10.1002/jcla.22576

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  19 in total

1.  Clinical value of jointly detection pleural fluid Midkine, pleural fluid adenosine deaminase, and pleural fluid carbohydrate antigen 125 in the identification of nonsmall cell lung cancer-associated malignant pleural effusion.

Authors:  Fan Zhang; Junjun Wang; Xiaoyong Zheng; Lijuan Hu; Jie Chen; Feng Jiang; Yumin Wang
Journal:  J Clin Lab Anal       Date:  2018-05-23       Impact factor: 2.352

2.  Detection of malignant effusions: comparison of a telomerase assay and cytologic examination.

Authors:  R Braunschweig; P Yan; I Guilleret; F Delacretaz; F T Bosman; A Mihaescu; J Benhattar
Journal:  Diagn Cytopathol       Date:  2001-03       Impact factor: 1.582

Review 3.  NSCLC: An Update of Driver Mutations, Their Role in Pathogenesis and Clinical Significance.

Authors:  Robert C Black; Humera Khurshid
Journal:  R I Med J (2013)       Date:  2015-10-01

4.  Midkine is up-regulated in both cancerous and inflamed bowel, reflecting lymph node metastasis in colorectal cancer and clinical activity of ulcerative colitis.

Authors:  Malgorzata Krzystek-Korpacka; Sabina Gorska; Dorota Diakowska; Bartosz Kapturkiewicz; Magdalena Podkowik; Andrzej Gamian; Iwona Bednarz-Misa
Journal:  Cytokine       Date:  2016-09-28       Impact factor: 3.861

5.  Midkine: an emerging target of drug development for treatment of multiple diseases.

Authors:  Takashi Muramatsu; Kenji Kadomatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 6.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

Review 7.  Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases.

Authors:  Takashi Muramatsu
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

8.  Serum midkine levels are increased in patients with various types of carcinomas.

Authors:  S Ikematsu; A Yano; K Aridome; M Kikuchi; H Kumai; H Nagano; K Okamoto; M Oda; S Sakuma; T Aikou; H Muramatsu; K Kadomatsu; T Muramatsu
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

9.  Perimembrane Aurora-A expression is a significant prognostic factor in correlation with proliferative activity in non-small-cell lung cancer (NSCLC).

Authors:  Eiji Ogawa; Kazumasa Takenaka; Hiromichi Katakura; Masashi Adachi; Yosuke Otake; Yoshinobu Toda; Hirokazu Kotani; Toshiaki Manabe; Hiromi Wada; Fumihiro Tanaka
Journal:  Ann Surg Oncol       Date:  2007-11-28       Impact factor: 5.344

10.  Identifying Malignant Pleural Effusion by A Cancer Ratio (Serum LDH: Pleural Fluid ADA Ratio).

Authors:  Akash Verma; John Abisheganaden; R W Light
Journal:  Lung       Date:  2015-12-17       Impact factor: 2.584

View more
  4 in total

1.  Clinical value of jointly detection pleural fluid Midkine, pleural fluid adenosine deaminase, and pleural fluid carbohydrate antigen 125 in the identification of nonsmall cell lung cancer-associated malignant pleural effusion.

Authors:  Fan Zhang; Junjun Wang; Xiaoyong Zheng; Lijuan Hu; Jie Chen; Feng Jiang; Yumin Wang
Journal:  J Clin Lab Anal       Date:  2018-05-23       Impact factor: 2.352

2.  [Detection of carcinoembryonic antigen levels in pleural effusion and serum and their ratio for differential diagnosis of pleural effusion resulting from tuberculosis and lung cancer].

Authors:  Ruicheng Li; Zhaowei Gao; Ke Dong; Huiping Wang; Huizhong Zhang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-02-28

3.  Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor.

Authors:  Jian Wang; Zhe-Xiang Feng; Tao Ren; Wei-Yu Meng; Imran Khan; Xing-Xing Fan; Hu-Dan Pan; Liang Liu; Yi-Jun Tang; Xiao-Jun Yao; Run-Ze Li; Mei-Fang Wang; Elaine Lai-Han Leung
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

4.  Multiplexed molecular profiling of lung cancer with malignant pleural effusion using next generation sequencing in Chinese patients.

Authors:  Xingya Ruan; Yonghua Sun; Wei Wang; Jianwei Ye; Daoyun Zhang; Ziying Gong; Mingxia Yang
Journal:  Oncol Lett       Date:  2020-03-05       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.